Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.21 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in retinal ganglion cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1948
Sealed predictions
- CLEC2L in dopamine neurons, braak-0.38 (p 0.316) → -0.27 (p 0.485)receipt 1955
Swarm cases
receipt 1955: CLEC2L in dopamine neurons, braak
- power
- full sample -0.21 (p 0.398, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.549, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.12, sign flips 0; without severely affected donors -0.21 (p 0.398, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CLEC2L in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts